Literature DB >> 25342117

Comparison of EQ-5D and SF-6D utilities in Pompe disease.

T A Kanters1, W K Redekop, M E Kruijshaar, A T van der Ploeg, M P M H Rutten-van Mölken, L Hakkaart.   

Abstract

PURPOSE: Comparative studies between Euroqol-5D (EQ-5D) and ShortForm 6D (SF-6D) utilities have been performed for a number of diseases, but not yet for orphan diseases. Pompe disease is an orphan disease with a prevalence of <5/10,000, characterized by impaired ambulatory and pulmonary functioning. We compared the psychometric properties of EQ-5D and SF-6D in patients with this disease and assessed their convergent validity, discriminative ability and sensitivity to change.
METHODS: EQ-5D utilities and SF-6D utilities were computed using the UK value set. Dimensions and utilities of the two instruments were compared by correlation coefficients and descriptive statistics. We assessed whether EQ-5D and SF-6D were able to discriminate between different levels of severity and examined sensitivity to change for patients with multiple observations.
RESULTS: Correlations between theoretically related dimensions of the EQ-5D and SF-6D were highly significant and were moderate to strong (range rho = 0.409-0.564). Utility values derived from the two instruments were similar (mean EQ-5D = 0.670; mean SF-6D = 0.699) and correlated strongly (rho = 0.591). Discriminative properties were somewhat better for EQ-5D; mean changes and effect sizes were better for SF-6D.
CONCLUSIONS: Overall, we conclude that both instruments appear to be equally appropriate with respect to assessing utilities in Pompe disease, but neither of them performed excellently. The descriptive system of the SF-6D describes health states for Pompe disease more accurately. EQ-5D showed better discriminative properties. The SF-6D performed better with respect to sensitivity to change.

Entities:  

Mesh:

Year:  2014        PMID: 25342117     DOI: 10.1007/s11136-014-0833-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

Review 2.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

3.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

4.  Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

Authors:  N A M E Van der Beek; M L C Hagemans; A J J Reuser; W C J Hop; A T Van der Ploeg; P A Van Doorn; J H J Wokke
Journal:  Neuromuscul Disord       Date:  2008-12-11       Impact factor: 4.296

5.  Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.

Authors:  N A M E van der Beek; C I van Capelle; K I van der Velden-van Etten; W C J Hop; B van den Berg; A J J Reuser; P A van Doorn; A T van der Ploeg; H Stam
Journal:  Mol Genet Metab       Date:  2011-06-24       Impact factor: 4.797

6.  The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status.

Authors:  Helen M McTaggart-Cowan; Carlo A Marra; Yaling Yang; John E Brazier; Jacek A Kopec; J Mark FitzGerald; Aslam H Anis; Larry D Lynd
Journal:  Qual Life Res       Date:  2008-02-15       Impact factor: 4.147

7.  The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies.

Authors:  Manuela Joore; Danielle Brunenberg; Patricia Nelemans; Emiel Wouters; Petra Kuijpers; Adriaan Honig; Danielle Willems; Peter de Leeuw; Johan Severens; Annelies Boonen
Journal:  Value Health       Date:  2009-10-29       Impact factor: 5.725

8.  Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D.

Authors:  A Szende; N K Leidy; E Ståhl; K Svensson
Journal:  Qual Life Res       Date:  2008-12-23       Impact factor: 4.147

Review 9.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

10.  A comparison of the EQ-5D and SF-6D across seven patient groups.

Authors:  John Brazier; Jennifer Roberts; Aki Tsuchiya; Jan Busschbach
Journal:  Health Econ       Date:  2004-09       Impact factor: 3.046

View more
  3 in total

1.  Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.

Authors:  Carmen Selva-Sevilla; Paula Ferrara; Manuel Gerónimo-Pardo
Journal:  Eur J Health Econ       Date:  2020-02-17

Review 2.  A Systematic Review of the Health Economics of Pompe Disease.

Authors:  Benedikt Schoser; Andreas Hahn; Emma James; Digant Gupta; Matthew Gitlin; Suyash Prasad
Journal:  Pharmacoecon Open       Date:  2019-12

Review 3.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.